This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee (9 November 2012)
| Read the full announcement in PDF format |
Bagsværd, Denmark, 9 November 2012 Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart.
Further information
| Media: | ||
| Mike Rulis | +45 4442 3573 | mike@novonordisk.com |
| Ambre Morley (US) | +1 609 216 5240 | abmo@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
| Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
| Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
| Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
Company announcement No 72 /2012
